Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_provenance.
- NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_assertion description "[Intervention trials of the synthetic nrf2 activator, bardoloxone methyl, in patients with advanced diabetic nephropathy, showing improvement of renal function and decreased inflammation, suggest that nrf2 activators may have therapeutic benefit in chronic renal failure.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_provenance.
- NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_assertion evidence source_evidence_literature NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_provenance.
- NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_assertion SIO_000772 22200442 NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_provenance.
- NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_assertion wasDerivedFrom befree-20140225 NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_provenance.
- NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_assertion wasGeneratedBy ECO_0000203 NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_provenance.
- befree-20140225 importedOn "2014-02-25" NP209580.RAB11ZaQ_z48iv9Lgt3n6RsO5FlNLjVCVe2AoO22zIlbI130_provenance.